Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes
NCT01499108 on ClinicalTrials.gov · last registry update 2015-02-02
A small phase 4 — 32 participants, against a typical 75. The sponsor logged completion for July 2013. Primary outcome, as filed: Change in ambulatory blood pressure. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Peter Rossing
- Sponsor type
- Other
- Enrollment
- 32
- Started
- 2012-08
- Primary completion
- 2013-07 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in ambulatory blood pressure
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.